S
Sanjay Kaul
Researcher at Cedars-Sinai Medical Center
Publications - 222
Citations - 25862
Sanjay Kaul is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Randomized controlled trial & Myocardial infarction. The author has an hindex of 67, co-authored 215 publications receiving 22556 citations. Previous affiliations of Sanjay Kaul include University of California, Los Angeles & Baylor University Medical Center.
Papers
More filters
Journal ArticleDOI
Expression Tenascin-C in Human Coronary Atherosclerotic Plaque
Journal ArticleDOI
Big topics for diabetes care in 2018: Clinical guidelines, costs of diabetes, and information technology
Matthew C. Riddle,George L. Bakris,Andrew J.M. Boulton,Lawrence Blonde,David A. D'Alessio,Eddie L. Greene,Mary de Groot,Korey K. Hood,Frank B. Hu,Steven E. Kahn,Sanjay Kaul,Derek LeRoith,Robert G. Moses,Stephen S. Rich,Julio Rosenstock,William V. Tamborlane,Judith Wylie-Rosett,Lyn Reynolds +17 more
TL;DR: At the midpoint of 2018, Diabetes Care’s editorial committee customarily presents a midyear report of activities and progress, in addition to a satisfying array of original scientific reports, important feature articles of current interest and a significant new initiative.
Journal ArticleDOI
By Desperate Appliance Relieved? On the Clinical Relevance of Risk Stratification to Therapeutic Decision-Making
George A. Diamond,Sanjay Kaul +1 more
TL;DR: In conclusion, the clinical appropriateness of risk stratification must not be assumed and guidelines specific to a particular disease and a particular treatment should be founded on prospective empiric validation.
Journal ArticleDOI
Therapeutic Concentrations of Heparin Augment Platelet Activation at the Time of Coronary Angiography
Tasneem Z. Naqvi,Prediman K. Shah,Pamela A. Ivey,Mia D. Molloy,Patricia Linn,Mariana Linker-Israeli,Bojan Cercek,Sanjay Kaul +7 more
TL;DR: Bolus administration of intravenous heparin augmented PLT activation in patients at clinically relevant anticoagulant concentrations may have implications for optimal dosing strategy forHeparin as an antithrombotic agent in clinical situations characterized by platelet-dependent thromBotic events.
Journal ArticleDOI
Improved prospects for IVUS in identifying vulnerable plaques
Sanjay Kaul,George A. Diamond +1 more
TL;DR: For many physicians, the holy grail of prevention is to identify thrombosis-prone “vulnerable” plaques before they rupture or become destabilized.